Literature DB >> 8895760

Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression.

S Geley1, B L Hartmann, M Hala, E M Strasser-Wozak, K Kapelari, R Kofler.   

Abstract

The ability of glucocorticoids (GCs) to induce death in lymphoid-origin cells is the basis for their frequent use in the therapy of various human hematological malignancies. However, the occurrence of primary or secondary GC resistance limits their clinical usefulness. Prior investigations into the mechanism of GC resistance in established human leukemic cell lines revealed loss-of-function mutations in the GC receptor (GR) gene. In this study, we analyzed the GC-resistant human acute T-cell leukemia line CEM-C1, which has been reported to express biochemically functional GR and, thus, was thought to owe its GC resistance to signal transduction changes distal from the GR. Radioligand binding assays revealed a 2-3-fold lower expression of GR in CEM-C1 than in the GC-sensitive sister cell line CEM-C7H2. Analysis of transcriptional activity using mouse mammary tumor virus-long terminal repeat-controlled chloramphenicol acetyltransferase expression in transient transfection assays confirmed the expression of functional GR in CEM-C1 but at levels lower than those in CEM-C7H2 cells. Upon molecular analyses of the GR gene and its transcripts, we found that CEM-C1 cells were heterozygous for the ligand binding domain L753F point mutation in exon 9, which is also present in GC-sensitive CEM-C7H2. No mutations, however, were found on the second GR allele of CEM-C1. To test the possibility that resistance in CEM-C1 cells might be caused by insufficient expression of GR, we established several cell lines stably transfected with rat GR expression vectors. These cell lines differed in exogenous GR expression as determined by Northern blotting and radioligand binding assays. The GR expression level in individual lines correlated well with their sensitivity to GC-induced apoptosis. Thus, GC resistance of CEM-C1 cells might be due to subthreshold expression of functional GR rather than defects in signal transduction pathways distal from the GR. Since several clinical investigations showed a correlation between reduced GR expression and poor response to GC-containing treatment, the CEM-C1 line may represent a valid model for GC resistance in human acute T-cell leukemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 2.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

3.  Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Authors:  Michael A Tessel; Ashley L Benham; Nancy L Krett; Steven T Rosen; Preethi H Gunaratne
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

4.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

5.  Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.

Authors:  Chuan-dong Geng; Wayne V Vedeckis
Journal:  Biochemistry       Date:  2010-10-19       Impact factor: 3.162

6.  Abnormal expression and distribution of heat shock protein 90: potential etiologic immunoendocrine mechanism of glucocorticoid resistance in idiopathic nephrotic syndrome.

Authors:  Juan Ouyang; Tang Jiang; Min Tan; Yinpeng Cui; Xiaoyan Li
Journal:  Clin Vaccine Immunol       Date:  2006-04

7.  Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Authors:  Anica M Wandler; Benjamin J Huang; Jeffrey W Craig; Kathryn Hayes; Hannah Yan; Lauren K Meyer; Alessandro Scacchetti; Gabriela Monsalve; Monique Dail; Qing Li; Jasmine C Wong; Olga Weinberg; Robert P Hasserjian; Scott C Kogan; Philip Jonsson; Keith Yamamoto; Deepak Sampath; Joy Nakitandwe; James R Downing; Jinghui Zhang; Jon C Aster; Barry S Taylor; Kevin Shannon
Journal:  Leukemia       Date:  2020-02-17       Impact factor: 11.528

8.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

9.  Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL).

Authors:  Alexandra M Cantley; Matthew Welsch; Alberto Ambesi-Impiombato; Marta Sanchez-Martin; Mi-Yeon Kim; Andras Bauer; Adolfo Ferrando; Brent R Stockwell
Journal:  ACS Med Chem Lett       Date:  2014-04-25       Impact factor: 4.345

10.  Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Authors:  T Melarangi; J Zhuang; K Lin; N Rockliffe; A G Bosanquet; M Oates; J R Slupsky; A R Pettitt
Journal:  Cell Death Dis       Date:  2012-08-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.